Literature DB >> 16505649

Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit.

Pieter O Depuydt1, Stijn I Blot, Dominique D Benoit, Geert W Claeys, Gerda L Verschraegen, Koenraad H Vandewoude, Dirk P Vogelaers, Johan M Decruyenaere, Francis A Colardyn.   

Abstract

OBJECTIVE: To study the occurrence of multiple-drug-resistant pathogens in nosocomial bloodstream infection associated with pneumonia. To evaluate prediction of multiple drug resistance by systematic surveillance cultures.
DESIGN: A retrospective study of a prospectively gathered cohort.
SETTING: Fifty-four-bed adult medical-surgical intensive care unit of a tertiary hospital. PATIENTS: One hundred twelve intensive care unit patients with nosocomial bloodstream infection associated with pneumonia from 1992 through 2001.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Concordance of blood cultures with prior surveillance culture was assessed. Surveillance cultures were taken routinely as thrice weekly urinary cultures and oral swabs, once weekly anal swabs, and thrice weekly tracheal aspirates in intubated patients. Tracheal surveillance cultures from 48 to 96 hrs before bloodstream infection and surveillance cultures from any site during the same intensive care unit episode but >or=48 hrs before bloodstream infection were evaluated separately. Forty-four bloodstream infections (39%) were caused by a multiple-drug-resistant pathogen. Multiple-drug-resistant pathogens were predicted by tracheal surveillance culture in 70% (concordant); in 15%, tracheal surveillance culture grew a multiple-drug-resistant pathogen not found in blood cultures (discordant). Multiple-drug-resistant pathogens were predicted by any surveillance culture in 88%, but these surveillance cultures grew additional multiple-drug-resistant pathogens not causing bloodstream infection in up to 46% of patients. In 86% of bloodstream infections, early (i.e., within 48 hrs) antibiotic therapy was appropriate. Patients were divided into four risk categories for multiple-drug-resistant bloodstream infection based on length of prior intensive care unit stay and prior antibiotic exposure. In patients with two risk factors, knowledge of surveillance cultures increased appropriateness of early antibiotic therapy from 75-79% to 90% (p<.05) while limiting use of broad-spectrum antibiotics such as antipseudomonal betalactams, fluoroquinolones, and carbapenems.
CONCLUSIONS: In our intensive care unit, tracheal surveillance culture predicted multiple-drug-resistant etiology of bloodstream infection associated with pneumonia in 70% of patients but yielded discordant resistant pathogens in 15%. In the subgroup of patients with two risk factors for multiple-drug-resistant infection, incorporating results of surveillance cultures moderately contributed to adequacy of early antibiotic therapy while limiting antibiotic consumption.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505649     DOI: 10.1097/01.CCM.0000201405.16525.34

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  21 in total

Review 1.  Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units.

Authors:  Dirk Vogelaers; Stijn Blot; Andries Van den Berge; Philippe Montravers
Journal:  Drugs       Date:  2021-05-26       Impact factor: 9.546

2.  Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.

Authors:  Pieter Depuydt; Dominique Benoit; Dirk Vogelaers; Geert Claeys; Gerda Verschraegen; Koenraad Vandewoude; Johan Decruyenaere; Stijn Blot
Journal:  Intensive Care Med       Date:  2006-09-16       Impact factor: 17.440

3.  Evidence-based guidelines for the prevention of ventilator-associated pneumonia: results of a knowledge test among intensive care nurses.

Authors:  Stijn I Blot; Sonia Labeau; Dominique Vandijck; Paul Van Aken; Brigitte Claes
Journal:  Intensive Care Med       Date:  2007-06-01       Impact factor: 17.440

4.  Maximizing rates of empiric appropriate antibiotic therapy with minimized use of broad-spectrum agents: are surveillance cultures the key?

Authors:  S Blot; P Depuydt; D Vogelaers
Journal:  Intensive Care Med       Date:  2008-08-19       Impact factor: 17.440

5.  The role of surveillance cultures in the prediction of susceptibility patterns of Gram-negative bacilli in the intensive care unit.

Authors:  H Baba; G R Nimmo; A M Allworth; R J Boots; Y Hayashi; J Lipman; D L Paterson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-11       Impact factor: 3.267

Review 6.  Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis.

Authors:  Nele Brusselaers; Sonia Labeau; Dirk Vogelaers; Stijn Blot
Journal:  Intensive Care Med       Date:  2012-11-28       Impact factor: 17.440

7.  De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli.

Authors:  N Shime; T Kosaka; N Fujita
Journal:  Infection       Date:  2012-12-20       Impact factor: 3.553

8.  Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia.

Authors:  P Depuydt; D Benoit; D Vogelaers; J Decruyenaere; D Vandijck; G Claeys; G Verschraegen; S Blot
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

Review 9.  Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms.

Authors:  Katherine Yang; B Joseph Guglielmo
Journal:  Ann Pharmacother       Date:  2007-07-31       Impact factor: 3.154

10.  Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures.

Authors:  Katherine Yang; Hanjing Zhuo; B Joseph Guglielmo; Jeanine Wiener-Kronish
Journal:  Ann Pharmacother       Date:  2008-11-25       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.